These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25226218)

  • 1. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design.
    Soto M; Andrieu S; Nourhashemi F; Ousset PJ; Ballard C; Robert P; Vellas B; Lyketsos CG; Rosenberg PB
    Int Psychogeriatr; 2014 Sep; ():1-17. PubMed ID: 25226218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force.
    Soto M; Abushakra S; Cummings J; Siffert J; Robert P; Vellas B; Lyketsos CG;
    J Prev Alzheimers Dis; 2015 Sep; 2(3):184-188. PubMed ID: 26413494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
    Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapies for sleep disturbances in Alzheimer's disease.
    McCleery J; Cohen DA; Sharpley AL
    Cochrane Database Syst Rev; 2014 Mar; (3):CD009178. PubMed ID: 24659320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapies for sleep disturbances in dementia.
    McCleery J; Cohen DA; Sharpley AL
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009178. PubMed ID: 27851868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
    Ostinelli EG; Brooke-Powney MJ; Li X; Adams CE
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD009377. PubMed ID: 28758203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for idiopathic intracranial hypertension.
    Piper RJ; Kalyvas AV; Young AM; Hughes MA; Jamjoom AA; Fouyas IP
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD003434. PubMed ID: 26250102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressants for the treatment of depression in people with cancer.
    Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011006. PubMed ID: 29683474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
    Banerjee S; Farina N; Henderson C; High J; Stirling S; Shepstone L; Fountain J; Ballard C; Bentham P; Burns A; Fox C; Francis P; Howard R; Knapp M; Leroi I; Livingston G; Nilforooshan R; Nurock S; O'Brien J; Price A; Thomas AJ; Swart AM; Telling T; Tabet N
    Health Technol Assess; 2023 Oct; 27(23):1-108. PubMed ID: 37929672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease.
    Herrmann N; Wang HJ; Song BX; Bawa KK; Lanctôt KL
    Expert Opin Drug Saf; 2022 Oct; 21(10):1289-1301. PubMed ID: 36252087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
    Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.